JP2011523353A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523353A5
JP2011523353A5 JP2011507588A JP2011507588A JP2011523353A5 JP 2011523353 A5 JP2011523353 A5 JP 2011523353A5 JP 2011507588 A JP2011507588 A JP 2011507588A JP 2011507588 A JP2011507588 A JP 2011507588A JP 2011523353 A5 JP2011523353 A5 JP 2011523353A5
Authority
JP
Japan
Prior art keywords
protein
overcharged
complex
cell
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041984 external-priority patent/WO2009134808A2/en
Publication of JP2011523353A publication Critical patent/JP2011523353A/ja
Publication of JP2011523353A5 publication Critical patent/JP2011523353A5/ja
Pending legal-status Critical Current

Links

JP2011507588A 2008-04-28 2009-04-28 細胞透過のための過剰に荷電されたタンパク質 Pending JP2011523353A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4837008P 2008-04-28 2008-04-28
US61/048,370 2008-04-28
US10528708P 2008-10-14 2008-10-14
US61/105,287 2008-10-14
PCT/US2009/041984 WO2009134808A2 (en) 2008-04-28 2009-04-28 Supercharged proteins for cell penetration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014114885A Division JP2014159484A (ja) 2008-04-28 2014-06-03 細胞透過のための過剰に荷電されたタンパク質

Publications (2)

Publication Number Publication Date
JP2011523353A JP2011523353A (ja) 2011-08-11
JP2011523353A5 true JP2011523353A5 (enExample) 2012-05-24

Family

ID=41255735

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011507588A Pending JP2011523353A (ja) 2008-04-28 2009-04-28 細胞透過のための過剰に荷電されたタンパク質
JP2014114885A Pending JP2014159484A (ja) 2008-04-28 2014-06-03 細胞透過のための過剰に荷電されたタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014114885A Pending JP2014159484A (ja) 2008-04-28 2014-06-03 細胞透過のための過剰に荷電されたタンパク質

Country Status (7)

Country Link
US (1) US20110112040A1 (enExample)
EP (1) EP2297182A4 (enExample)
JP (2) JP2011523353A (enExample)
CN (1) CN102066405B (enExample)
AU (1) AU2009243187C1 (enExample)
CA (1) CA2725601A1 (enExample)
WO (1) WO2009134808A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378772B (zh) * 2005-08-05 2013-12-04 阿拉伊姆药品公司 组织保护性肽及其用途
AU2007256780B2 (en) 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
US9221886B2 (en) 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
WO2012071549A2 (en) 2010-11-24 2012-05-31 Clontech Laboratories, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
EP2668276A4 (en) * 2011-01-26 2014-04-23 Clontech Lab Inc Enhanced protein transduction
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012170372A2 (en) * 2011-06-08 2012-12-13 University Of Cincinnati Prna mutlivalent junction domain for use in stable multivalent rna nanoparticles
AU2012284365B2 (en) 2011-07-15 2017-04-20 The General Hospital Corporation Methods of transcription activator like effector assembly
EP2734622B1 (en) 2011-07-19 2018-09-05 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
BR112014004014A2 (pt) * 2011-08-23 2020-10-27 President And Fellows Of Harvard College partículas de peptídeos e seus usos
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドModernaTX,Inc. 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013101690A1 (en) * 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
WO2013142859A2 (en) 2012-03-23 2013-09-26 Wuhan Peptech Pharmaceutical Co., Ltd. Fusion proteins of superfolder green fluorescent protein and use thereof
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
CN103031337A (zh) * 2012-09-28 2013-04-10 北京吉利奥生物科技发展有限公司 一种小核酸分子快递技术
WO2014059255A1 (en) 2012-10-12 2014-04-17 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
AU2014214719B2 (en) 2013-02-07 2020-02-13 The General Hospital Corporation Tale transcriptional activators
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン,インコーポレイテッド CRISPR関連方法および支配gRNAのある組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CN104127868B (zh) * 2014-05-06 2016-03-02 卢戌 一种肿瘤疫苗及其应用
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CN113929766A (zh) * 2015-02-18 2022-01-14 麻省理工学院 水溶性跨膜蛋白及其制备和使用方法
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
CN105219877B (zh) * 2015-11-06 2018-09-25 中国医学科学院北京协和医院 Ccdc59的激动剂在制备骨性关节炎药物中的应用
US10604558B2 (en) 2016-01-05 2020-03-31 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018047959A1 (ja) * 2016-09-12 2018-03-15 株式会社Hirotsuバイオサイエンス 線虫の嗅覚に基づく匂い物質に対する走性行動の評価方法、並びに該評価方法に用いるシャーレおよび行動評価系
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP6797375B2 (ja) * 2016-12-26 2020-12-09 学校法人 久留米大学 生体標本作製器具および生体標本作製方法
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11723985B2 (en) 2017-09-08 2023-08-15 Cytoseek Limited Protein delivery to membranes
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201902992D0 (en) 2019-03-06 2019-04-17 Cytoseek Ltd Product and method
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20210023236A1 (en) * 2019-07-26 2021-01-28 Massachusetts Institute Of Technology Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20240183842A1 (en) * 2021-04-22 2024-06-06 The General Hospital Corporation Supercharged Biovesicles and Methods of Use Thereof
CN114452266B (zh) * 2022-02-09 2023-05-19 南京凯玛生物科技有限公司 一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) * 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6399754B1 (en) * 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6127533A (en) * 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
US6403779B1 (en) * 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
WO2001076637A2 (en) * 2000-04-12 2001-10-18 Implyx Ltd. Peptide conjugates for drug delivery
AU2001275257A1 (en) * 2000-06-05 2001-12-17 Scimed Life Systems, Inc. Et.Al. Methods and devices for the treatment of urinary incontinence
ATE448306T1 (de) * 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
US20040102606A1 (en) * 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
JP4371812B2 (ja) * 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ マイクロrna分子
US20030134352A1 (en) * 2002-01-04 2003-07-17 Freimuth Paul I. Facilitating protein folding and solubility by use of peptide extensions
CA2472725C (en) * 2002-01-16 2015-08-11 Genencor International, Inc. Multiply-substituted protease variants
US9637528B2 (en) * 2002-04-24 2017-05-02 Los Alamos National Security, Llc Method of generating ploynucleotides encoding enhanced folding variants
US7271241B2 (en) * 2002-04-24 2007-09-18 Los Alamos National Security, Llc Directed evolution methods for improving polypeptide folding and solubility and superfolder fluorescent proteins generated thereby
AU2003276131A1 (en) * 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
JP3996028B2 (ja) * 2002-09-30 2007-10-24 株式会社日本触媒 蛋白質又はペプチドの細胞内導入方法
AU2004204456A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1593060A2 (en) * 2003-01-21 2005-11-09 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
DK1954713T3 (da) * 2005-11-04 2013-02-11 Evrogen Jsc Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
US7452973B2 (en) * 2005-11-07 2008-11-18 Wisconsin Alumni Research Foundation Cell-permeable fluorescent proteins
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
AU2007256780B2 (en) * 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration

Similar Documents

Publication Publication Date Title
CN102066405B (zh) 用于细胞穿透的超荷电蛋白
JP2011523353A5 (enExample)
JP2016008217A (ja) 細胞透過のための過剰に荷電されたタンパク質
EP3280739B1 (en) Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
US10538570B2 (en) Targeted and modular exosome loading system
US9982267B2 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
EP4556567A2 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
JP6001082B2 (ja) 細胞透過能を改善した改良形の新規巨大分子伝達ドメインの開発及びその利用方法
KR101258279B1 (ko) 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
CN101395180A (zh) 用作细胞穿膜肽的肽
KR101647804B1 (ko) 신규 세포투과 펩타이드 및 이의 용도
JP7611811B2 (ja) 細胞膜透過性ペプチドとして使用するためのペプチド
KR101559974B1 (ko) siRNA 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
KR101579879B1 (ko) siRNA 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물
WO2015080943A1 (en) Novel cell-penetrating compositions and methods using same
US8653236B2 (en) Therapeutic agents
JP2023545401A (ja) 高度な細胞透過性ペプチド担体
US20250101071A1 (en) Binding proteins specific for cd32a
KR20250116633A (ko) 눈의 세포 및 조직으로의 치료제의 arrdc1-매개된 미세소포-기반 전달
WO2023004150A2 (en) Compositions and methods for treatment of neurodegenerative diseases
Okuda et al. Enhanced gene delivery and/or efficacy by functional peptide and protein